BridgeBio Pharma Inc
BBIO61.370USD
-0.610-0.98%
Handelsschluss 11/04, 16:00（ET）Kurse um 15 Minuten verzögert
11.82BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über BridgeBio Pharma Inc Unternehmen
BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering, creating, testing and delivering transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. The Company's pipeline of development programs ranges from early science to advanced clinical trials that include Acoramidis (AG10), a next-generation small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of amyloidosis TTR (ATTR); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI), as a treatment option for children with achondroplasia; Encaleret, a small molecule antagonist of the calcium sensing receptor (CaSR) for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, an investigational, orally administered, small molecule substrate supplementation therapy that the Company is developing for the treatment of LGMD2I, also known as LGMDR9.
BridgeBio Pharma Inc Informationen
BörsenkürzelBBIO
Name des UnternehmensBridgeBio Pharma Inc
IPO-datumJun 27, 2019
CEODr. Neil Kumar, Ph.D.
Anzahl der mitarbeiter725
WertpapierartOrdinary Share
GeschäftsjahresendeJun 27
Addresse3160 Porter Dr.
StadtPALO ALTO
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl94304
Telefon16503919740
Websitehttps://bridgebio.com/
BörsenkürzelBBIO
IPO-datumJun 27, 2019
CEODr. Neil Kumar, Ph.D.
Führungskräfte von BridgeBio Pharma Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Neil Kumar, Ph.D.
Dr. Neil Kumar, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
6.17M
+0.09%
Dr. Charles J. Homcy, M.D.
Dr. Charles J. Homcy, M.D.
Lead Director, Chairman of Pharmaceuticals
Lead Director, Chairman of Pharmaceuticals
916.67K
-24.66%
Mr. Ali J. Satvat
Mr. Ali J. Satvat
Independent Director
Independent Director
165.99K
+4.13%
Mr. James C. (Jim) Momtazee
Mr. James C. (Jim) Momtazee
Independent Director
Independent Director
95.08K
+7.45%
Dr. Thomas Trimarchi, Ph.D.
Dr. Thomas Trimarchi, Ph.D.
President, Chief Financial Officer
President, Chief Financial Officer
57.85K
-26.92%
Mr. Fred Hassan
Mr. Fred Hassan
Lead Independent Director
Lead Independent Director
25.89K
+34.14%
Mr. Ronald J. Daniels, J.D.
Mr. Ronald J. Daniels, J.D.
Independent Director
Independent Director
16.99K
+63.34%
Dr. Randal W. (Randy) Scott, Ph.D.
Dr. Randal W. (Randy) Scott, Ph.D.
Independent Director
Independent Director
15.59K
+73.21%
Ms. Jennifer E. Cook
Ms. Jennifer E. Cook
Independent Director
Independent Director
13.74K
+92.13%
Dr. Eric Aguiar, M.D.
Dr. Eric Aguiar, M.D.
Independent Director
Independent Director
6.59K
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Neil Kumar, Ph.D.
Dr. Neil Kumar, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
6.17M
+0.09%
Dr. Charles J. Homcy, M.D.
Dr. Charles J. Homcy, M.D.
Lead Director, Chairman of Pharmaceuticals
Lead Director, Chairman of Pharmaceuticals
916.67K
-24.66%
Mr. Ali J. Satvat
Mr. Ali J. Satvat
Independent Director
Independent Director
165.99K
+4.13%
Mr. James C. (Jim) Momtazee
Mr. James C. (Jim) Momtazee
Independent Director
Independent Director
95.08K
+7.45%
Dr. Thomas Trimarchi, Ph.D.
Dr. Thomas Trimarchi, Ph.D.
President, Chief Financial Officer
President, Chief Financial Officer
57.85K
-26.92%
Mr. Fred Hassan
Mr. Fred Hassan
Lead Independent Director
Lead Independent Director
25.89K
+34.14%
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Oct 6
Währung: USDAktualisiert: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
United States
71.53M
64.70%
Europe Middle East and Africa (EMEA)
35.05M
31.70%
Asia Pacific (APAC)
3.98M
3.60%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, Oct 24
Aktualisiert: Fri, Oct 24
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Viking Global Investors LP
9.23%
The Vanguard Group, Inc.
8.54%
Kohlberg Kravis Roberts & Co. L.P.
6.88%
BlackRock Institutional Trust Company, N.A.
6.17%
Janus Henderson Investors
4.81%
Andere
64.37%
Aktionäre
Aktionäre
Anteil
Viking Global Investors LP
9.23%
The Vanguard Group, Inc.
8.54%
Kohlberg Kravis Roberts & Co. L.P.
6.88%
BlackRock Institutional Trust Company, N.A.
6.17%
Janus Henderson Investors
4.81%
Andere
64.37%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
34.43%
Investment Advisor/Hedge Fund
33.14%
Hedge Fund
16.85%
Private Equity
8.85%
Individual Investor
4.72%
Research Firm
3.21%
Venture Capital
1.96%
Sovereign Wealth Fund
1.02%
Bank and Trust
0.60%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
653
194.03M
100.69%
-638.66K
2025Q2
626
190.36M
99.64%
-5.40M
2025Q1
628
200.01M
105.33%
-2.20M
2024Q4
586
190.11M
100.07%
-10.58M
2024Q3
566
185.43M
98.60%
-19.02M
2024Q2
541
188.12M
100.51%
-8.17M
2024Q1
529
185.29M
101.24%
-2.60M
2023Q4
525
179.04M
102.35%
-7.24M
2023Q3
519
174.99M
102.35%
-1.47M
2023Q2
503
162.75M
101.40%
-17.06M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Viking Global Investors LP
17.78M
9.3%
-822.74K
-4.42%
Aug 14, 2025
The Vanguard Group, Inc.
16.45M
8.61%
+1.58M
+10.64%
Jun 30, 2025
Kohlberg Kravis Roberts & Co. L.P.
13.26M
6.94%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
11.89M
6.22%
+714.59K
+6.39%
Jun 30, 2025
Janus Henderson Investors
9.28M
4.85%
+2.11M
+29.35%
Jun 30, 2025
Farallon Capital Management, L.L.C.
7.90M
4.13%
+2.17M
+37.85%
Jun 30, 2025
Kumar (Neil)
6.17M
3.23%
+5.69K
+0.09%
Aug 20, 2025
Aisling Capital Management LP
6.07M
3.17%
--
--
Jun 30, 2025
State Street Investment Management (US)
5.90M
3.08%
+146.98K
+2.56%
Jun 30, 2025
Two Sigma Investments, LP
4.02M
2.1%
+2.91M
+260.34%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sun, Nov 2
Aktualisiert: Sun, Nov 2
Name
Anteil
Tema Oncology ETF
5.03%
Franklin Genomic Advancements ETF
3.3%
Tema Heart & Health ETF
2.96%
Invesco Dorsey Wright Healthcare Momentum ETF
2.33%
Virtus LifeSci Biotech Products ETF
2.18%
SPDR S&P Biotech ETF
2.03%
Direxion Daily S&P Biotech Bull 3X Shares
1.16%
ProShares Ultra Nasdaq Biotechnology
1.03%
Federated Hermes MDT Small Cap Core ETF
1.03%
Invesco Nasdaq Biotechnology ETF
1%
Mehr Anzeigen
Tema Oncology ETF
Anteil5.03%
Franklin Genomic Advancements ETF
Anteil3.3%
Tema Heart & Health ETF
Anteil2.96%
Invesco Dorsey Wright Healthcare Momentum ETF
Anteil2.33%
Virtus LifeSci Biotech Products ETF
Anteil2.18%
SPDR S&P Biotech ETF
Anteil2.03%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil1.16%
ProShares Ultra Nasdaq Biotechnology
Anteil1.03%
Federated Hermes MDT Small Cap Core ETF
Anteil1.03%
Invesco Nasdaq Biotechnology ETF
Anteil1%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
